503B INSPECTION RESPONSE RECORD CAPA EFFECTIVENESS · CONTEMPORANEOUS

The investigator asks why the CAPA was closed.
This is the record that answers.

CAPA closure records show actions were completed. They rarely preserve the effectiveness reasoning that justified closure at the moment the decision was made. This record captures who determined recurrence risk was acceptably reduced, what evidence supported closure, what failure modes were considered and ruled out, and why the effectiveness window was sufficient.

$497 · per record · Built for 503B Designated Persons, QA leaders, and CAPA owners

This record is generated from your structured inputs only. ComplianceWorxs does not invent evidence, fabricate effectiveness conclusions, or substitute generic compliance language for recurrence reasoning. Gaps are flagged. Authorization belongs to the named decision-maker — not the platform.

RECORD — IN PREPARATION

Step 1 of 6 Investigator Question

DECISION TYPE — LOCKED CAPA Closure / Effectiveness Verification

Step 1 of 6 · Investigator Question

Start with the question the investigator will actually ask.

§01 Investigator Question

Restate the exact effectiveness question an FDA investigator would ask during a 503B inspection. Use inspection language — not a paraphrase. The investigator's pressure point is rarely "was it closed" — it's "how did you determine it was effective."

Primary FDA question *

Recurrence concern FDA would likely raise

Specific effectiveness determination being defended

Step 2 of 6 · Authorization Summary & Effectiveness Window

Who owns the closure — and why was the window long enough?

§02 Authorization Summary

The CAPA, the originating event, and the person who owns the effectiveness conclusion. Investigators reconstruct events at this granularity.

CAPA ID *

Originating deviation ID

Investigation reference

Procedure / SOP revised

Facility name

FDA FEI number

Sterile operation area

Closure date / time

Decision owner (name) *

Authorization lineage

Source evidence archive references

§03 Effectiveness Window

The investigator will ask why this window was sufficient. The answer must be defensible without retrospective adjustment.

Window start date

Window end date

Window prospectively defined before implementation?

Acceptance criteria established before implementation?

Window reasoning — why this duration is sufficient Number of operational cycles represented in window

Step 3 of 6 · Evidence Streams & Exclusions

What evidence supported closure — and what was deliberately excluded?

§04 Convergent Evidence Streams

Minimum three independent streams. The strength of the authorization is not in any single stream — it is in their convergence. Absence-of-deviations alone is not sufficient.

§05 Evidence Explicitly Not Relied Upon

Required. Evidence reviewed but consciously rejected from the effectiveness basis. Preserving exclusion logic is what makes the reasoning reconstructable in both directions. Examples: absence of deviations alone · analyst verbal confirmation · partial trend window · complaint absence · unverified manual logs · cross-facility assumptions.

Step 4 of 6 · Recurrence Hypotheses & Sterility Risk

What recurrence paths were ruled out, and how was contamination risk evaluated?

§06 Alternative Recurrence Hypotheses

Required. Recurrence pathways considered and ruled out. The investigator will reconstruct failure modes — this section demonstrates you reconstructed them first. Examples: procedural drift · analyst non-compliance reverting · equipment tampering · latent contamination signal · inadequate monitoring duration · training retention failure · absence-of-evidence closure.

§07 Sterility Assurance & Risk Evaluation

The reasoning investigators interrogate hardest in 503B effectiveness verification. Generic answers fail.

Contamination risk assessment *

Environmental trend outcome

Personnel monitoring status

Residual contamination concern Independent controls now preventing recurrence

Failure-mode analysis

Does single-control failure recreate original deviation?

Step 5 of 6 · Rationale, Regulatory & Residual Exposure

The reasoning, the regulatory anchors, and the residual risk you accepted.

§08 Authorization Rationale

The core of the record. Inspector-grade tone — operational, compressed, evidence-linked. No generic QA language. This is the reasoning the Dir QS & CAPA commits to before closure.

What did the authorizer explicitly review before closure? * What did the authorizer conclude at the time of closure? * Why is recurrence probability acceptably reduced? * Human judgment statement (one compressed line, signed with initials)

§09 Regulatory Alignment

Select the regulatory anchors the authorization reasoning aligns to. The IRR maps your reasoning to the sections cited.

21 CFR 211.192 Production record review & CAPA — effectiveness verification 21 CFR 211.100 Written procedures; deviations 21 CFR 211.113 Microbiological contamination control — sterile drug products 21 CFR 211.165 Testing & release for distribution USP <797> Sterile compounding USP <1116> Microbiological control of aseptic processing environments FDA 503B cGMP Guidance Outsourcing Facility (2020) FDA Quality Systems Guidance Closure on demonstrated effectiveness

§10 Residual Exposure

Bounded uncertainty. Inspectors expect honest acknowledgment of residual risk, not false certainty. CAPA effectiveness is window-bounded — name the conditions not represented in the window.

What residual risk remains? *

Why is residual risk acceptable?

Assumptions bounding the authorization

Future conditions that could invalidate closure

Controls continuing post-closure (routine, not CAPA-bounded)

Is extended monitoring required beyond closure?

Step 6 of 6 · Retrieval, Approval Chain & Delivery

Retrieval context, the approval chain, and where to send the record.

§11 Retrieval Context

The session conditions under which evidence was assembled. Real inspections challenge timing, retrieval sequence, and reviewer access — preserve them now.

Review session date / time

Session lead

Source systems accessed

Retrieval checklist reference

Deferred items at session close

Linked records (change controls, qualification packages, parent records)

§12 Approval Chain

The authorization lineage as it will appear on the record. Asymmetry is normal — inherited chain entries, partial fields, system-generated e-sig refs all reflect real operational behavior.

Closure authorizer title *

Risk eval co-reviewer

Quality Systems Manager reviewer

Internal audit reference

Notification chain (notified but not authorizer)

E-signature references / approval timestamps Review participants (other roles)

§13 Delivery

We email the unlocked CAPA Effectiveness IRR to this address after payment.

Email *

You'll see a preview of the record and gap analysis before payment. Payment unlocks the full authorization record.

The next inspection is the one you cannot reconstruct for.

The investigator asks why the CAPA was closed. This is the record that answers.

Your CAPA Effectiveness IRR — Preview

The investigator asks why the CAPA was closed.
This is the record that answers.